Application of T‐cell receptor repertoire as a novel monitor in dynamic tracking and assessment: A cohort‐study based on RA patients. Issue 24 (28th November 2022)

• Record Type: Journal Article
• Authors: Yang, Peiqing; He, Yijing; Qing, Pingying; Xu, Wangdong; Xie, Dan; Cazier, Jean‐Baptiste; Liu, Xiao; Varnai, Csilla; Zhou, Yi; Zhao, Yi; Tang, Huairong; Yin, Xiaoming; Liu, Yi
• Is Part Of: Journal of cellular and molecular medicine. Volume 26:Issue 24(2022)
• Page Start: 6042
• Page End: 6055
• Publication Date: 2022-11-28
• Subjects: biomarkers -- DMARDs -- next‐generation sequencing -- rheumatoid arthritis -- T‐cell receptor repertoire; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.17623
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: T‐cell receptor repertoire (TCRR) sequencing has been widely applied in many fields as a novel tool. This study explored characteristics of TCRR in detail with a cohort of 598 rheumatoid arthritis (RA) patients before and after anti‐rheumatic treatments. We highlighted the abnormal TCRR distribution in RA characterized by decreased diversity and increased proportion of hyperexpanded clones (HECs), which was potentially attributed to skewed usage of global V/J segments but not a few certain ones. Enriched motifs analysis in RA community demonstrated the huge heterogeneity of CDR3 sequences, so that individual factors are strongly recommended to be taken into consideration when it comes to clinical application of TCRR. Disease‐modifying antirheumatic drugs (DMARDs) can regulate immune system through recovery of TCRR richness to relieve symptoms. Remarkably, sensitive gene profile and advantageous gene profile were identified in this study as new biomarkers for different DMARDs regimens.